Brief: Lexicon Enrolls First Patient In Phase 2B Progress Study Of Lx9211 In Diabetic Peripheral Neuropathic Pain (Dpnp)
30/11/2023 13:04
Lexicon Pharmaceuticals Inc LXRX.O :
* LEXICON ENROLLS FIRST PATIENT IN PHASE 2B PROGRESS STUDY
OF
LX9211 IN DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP)
* LEXICON PHARMACEUTICALS INC - TOPLINE DATA FROM PROGRESS
IS
EXPECTED TO BE ANNOUNCED IN Q2 2025
Source text for Eikon: ID:nGNX3MMqxt
Further company coverage: LXRX.O
Recent news on Lexicon Pharmaceuticals
See all newsLexicon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Lexicon Pharmaceuticals posts Q2 net loss
Brief: Lexicon Pharmaceuticals Q2 EPS USD -0.07
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview